It was interesting that no questions were asked about the negotiations with Amgen, whether there were any other bidders (basically to get Coles to confirm his opening remarks). etc. Quite puzzling--I would have thought that the discussion regarding those negtiations would dominate the conference call.
Tony Coles made it clear in the opening remarks that they would not be answering any questions regarding the negotiations. One analyst did ask a question about retention of key employees during the negotiations, but that was as far as it went. It's very unlikely that the company will say anything more officially until there is a deal in place.